| abstract |
Provided is a marker for assessing sensitivity to an anticancer drug during the early stages after initiating treatment. This marker for assessing, during the early stages after initiating treatment, sensitivity to an anticancer drug containing oxaliplatin or a salt thereof, fluorouracil or a salt thereof, and levofolinate or a salt thereof comprises one or more molecules selected from the group consisting of 2AMAD, 2ABA, 2CYPR, 5OPRO, 6AHXA, ADEN, ASP, BETNC, CARB, CSSG, DOPM, GGLCY, GSSG, HYPT, METSF, N6MDA, NOMTR, PHEP, PRO and RIB5P. |